{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:10:14Z","timestamp":1790745014681,"version":"4.1.0"},"reference-count":36,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2001,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Limited response to idiotype vaccination in patients with myeloma suggests that there is a need to develop better immunotherapy strategies. It has been determined that the number of high-potency CMRF44+CD14\u2212CD19\u2212dendritic cells (DCs) in the blood of patients with myeloma (range, 0.03%-0.8% of mononuclear cells [MNCs]; n\u2009=\u200926) was not significantly different from that in controls (range, 0.05%-0.8% of MNCs; n\u2009=\u200913). Expression of the costimulatory molecules CD80 and CD86 on DCs from these patients (mean, 29%\u00b117% of MNCs and 85%\u00b110% of MNCs, respectively) was also normal (mean, 29%\u00b117% and 86%\u00b116% of MNCs, respectively). Up-regulation of CD80 expression in response to stimulation by human (hu)CD40LT + interleukin (IL)-2 was significantly reduced on the DCs of patients with myeloma during stable disease (n\u2009=\u20099) and was absent during progressive stages (n\u2009=\u20097) of disease. Similar effects were seen on B cells but not on monocytes of the same group of patients. CD86 expression on DCs was high before (86%) and after (89%) stimulation. Inhibition of CD80 up-regulation was neutralized by either anti\u2013transforming growth factor (TGF)\u2013\u03b21 or anti\u2013IL-10. Up-regulation of CD80 on DCs of controls was inhibited by rTGF-\u03b21 in a dose-dependent manner. Serum TGF-\u03b21 and IL-10 levels were normal in most patients studied. Cytoplasmic TGF-\u03b21 was increased in plasma cells during progressive disease. Thus patients with myeloma have normal numbers of DCs, but CD80 expression may fail to be up-regulated in the presence of huCD40LT because of tumor-derived TGF-\u03b21 or IL-10. Autologous high-potency DCs may have to be tested for CD80 up-regulation and biologically modified ex vivo before idiotype priming for immunotherapy.<\/jats:p>","DOI":"10.1182\/blood.v98.10.2992","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T12:46:40Z","timestamp":1027774000000},"page":"2992-2998","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":292,"title":["Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-\u03b21 and interleukin-10"],"prefix":"10.1182","volume":"98","author":[{"given":"Ross D.","family":"Brown","sequence":"first","affiliation":[{"name":"From the Institute of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, and the Mater Medical Research Institute, Brisbane, Queensland, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda","family":"Pope","sequence":"additional","affiliation":[{"name":"From the Institute of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, and the Mater Medical Research Institute, Brisbane, Queensland, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Murray","sequence":"additional","affiliation":[{"name":"From the Institute of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, and the Mater Medical Research Institute, Brisbane, Queensland, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Esdale","sequence":"additional","affiliation":[{"name":"From the Institute of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, and the Mater Medical Research Institute, Brisbane, Queensland, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Sze","sequence":"additional","affiliation":[{"name":"From the Institute of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, and the Mater Medical Research Institute, Brisbane, Queensland, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Gibson","sequence":"additional","affiliation":[{"name":"From the Institute of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, and the Mater Medical Research Institute, Brisbane, Queensland, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Joy","family":"Ho","sequence":"additional","affiliation":[{"name":"From the Institute of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, and the Mater Medical Research Institute, Brisbane, Queensland, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Hart","sequence":"additional","affiliation":[{"name":"From the Institute of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, and the Mater Medical Research Institute, Brisbane, Queensland, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Joshua","sequence":"additional","affiliation":[{"name":"From the Institute of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, and the Mater Medical Research Institute, Brisbane, Queensland, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021217062736400_B1","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1084\/jem.173.3.721","article-title":"Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation.","volume":"173","author":"Linsley","year":"1991","journal-title":"J Exp Med."},{"key":"2020021217062736400_B2","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1182\/blood.V84.10.3261.3261","article-title":"Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumour immunity.","volume":"84","author":"Guinan","year":"1994","journal-title":"Blood."},{"key":"2020021217062736400_B3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0268-960X(96)90040-5","article-title":"B7-mediated costimulation and the immune response.","volume":"10","author":"Schultz","year":"1996","journal-title":"Blood Rev."},{"key":"2020021217062736400_B4","first-page":"38","article-title":"Dendritic cell infection, depletion and dysfunction in HIV-infected individuals.","volume":"71","author":"Macatonia","year":"1990","journal-title":"Immunology."},{"key":"2020021217062736400_B5","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/blood.V93.2.728","article-title":"Monitoring human blood dendritic cell numbers in normal individuals and in stem cell transplantation.","volume":"93","author":"Fearnley","year":"1999","journal-title":"Blood."},{"key":"2020021217062736400_B6","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1182\/blood.V90.9.3245","article-title":"DC: unique leukocyte populations which control the primary immune reponse.","volume":"90","author":"Hart","year":"1997","journal-title":"Blood."},{"key":"2020021217062736400_B7","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.7326\/0003-4819-41-6-1152","article-title":"Recurrent pneumonia in multiple myeloma and some observations on immunologic response.","volume":"41","author":"Zinneman","year":"1954","journal-title":"Ann Intern Med."},{"key":"2020021217062736400_B8","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/ijc.2910230512","article-title":"Immune suppression in BALB\/c mice bearing the plasmacytoma TEPC-183: evidence for normal lymphocyte but defective macrophage function.","volume":"23","author":"Joshua","year":"1979","journal-title":"Int J Cancer."},{"key":"2020021217062736400_B9","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1182\/blood.V93.5.1487","article-title":"Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences.","volume":"93","author":"Raje","year":"1999","journal-title":"Blood."},{"key":"2020021217062736400_B10","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1046\/j.1365-2141.1997.3123128.x","article-title":"Dendritic cells generated from the blood of patients with multiple myeloma are phenotypically and functionally identical to those similarly produced from healthy donors.","volume":"98","author":"Pfeiffer","year":"1997","journal-title":"Br J Haematol."},{"key":"2020021217062736400_B11","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood.V94.2.673","article-title":"Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.","volume":"94","author":"Massaia","year":"1999","journal-title":"Blood."},{"key":"2020021217062736400_B12","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood.V93.7.2411","article-title":"Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: a feasibility study.","volume":"93","author":"Reichardt","year":"1999","journal-title":"Blood."},{"key":"2020021217062736400_B13","first-page":"957","article-title":"Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma.","volume":"4","author":"Wen","year":"1998","journal-title":"Clin Cancer Res."},{"key":"2020021217062736400_B14","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1046\/j.1365-2141.1998.00633.x","article-title":"Anti-idiotypic T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells.","volume":"100","author":"Dabadghao","year":"1998","journal-title":"Br J Haematol."},{"key":"2020021217062736400_B15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00002371-199705000-00001","article-title":"Reversal of tumor-induced immunosuppression: a new approach to cancer therapy.","volume":"20","author":"Wojtowicz-Praga","year":"1997","journal-title":"J Immunother."},{"key":"2020021217062736400_B16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1084\/jem.184.1.19","article-title":"Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells.","volume":"184","author":"Groux","year":"1996","journal-title":"J Exp Med."},{"key":"2020021217062736400_B17","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1084\/jem.177.4.925","article-title":"Activated T cells induce expression of B7\/BB1 on normal or leukemic B cells through a CD40-dependent signal.","volume":"177","author":"Ranheim","year":"1993","journal-title":"J Exp Med."},{"key":"2020021217062736400_B18","first-page":"4485","article-title":"Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells.","volume":"60","author":"Brossart","year":"2000","journal-title":"Cancer Res."},{"key":"2020021217062736400_B19","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.4049\/jimmunol.159.10.4772","article-title":"Induction of tolerance by IL-10-treated dendritic cells.","volume":"159","author":"Steinbrink","year":"1997","journal-title":"J Immunol."},{"key":"2020021217062736400_B20","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1445-5994.1989.tb00251.x","article-title":"Serum thymidine kinase as a marker of disease activity in patients with multiple myeloma.","volume":"19","author":"Brown","year":"1989","journal-title":"Aust N Z J Med."},{"key":"2020021217062736400_B21","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1046\/j.1365-2141.1997.9942643.x","article-title":"Australian Leukaemia Study Group Myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma.","volume":"97","author":"Joshua","year":"1997","journal-title":"Br J Haematol."},{"key":"2020021217062736400_B22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/sj.bmt.1700866","article-title":"Plasma cells in peripheral blood stem cell harvests from patients with multiple myeloma are predominantly polyclonal.","volume":"20","author":"Pope","year":"1997","journal-title":"Bone Marrow Transplant."},{"key":"2020021217062736400_B23","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1126\/science.276.5320.1851","article-title":"Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients.","volume":"276","author":"Rettig","year":"1997","journal-title":"Science."},{"key":"2020021217062736400_B24","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1046\/j.1365-2141.1999.01628.x","article-title":"Kaposi's sarcoma-associated herpesvirus (KSHV\/HHV-8) DNA sequences are absent in leukapheresis products and ex vivo expanded CD34+ cells from multiple myeloma patients.","volume":"106","author":"De Greef","year":"1999","journal-title":"Br J Haematol."},{"key":"2020021217062736400_B25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1023\/A:1008320717531","article-title":"Bone marrow-derived dendritic cells from patients with multiple myeloma cultured with three distinct protocols do not bear Kaposi's sarcoma associated herpesvirus DNA.","volume":"10","author":"Bellos","year":"1999","journal-title":"Ann Oncol."},{"key":"2020021217062736400_B26","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1182\/blood.V93.3.1110","article-title":"Absence of Kaposi's sarcoma-associated herpesvirus DNA sequences in multiple myeloma [letter].","volume":"93","author":"Corbellino","year":"1999","journal-title":"Blood."},{"key":"2020021217062736400_B27","doi-asserted-by":"crossref","first-page":"698","DOI":"10.4049\/jimmunol.164.2.698","article-title":"Vaccination with mouse mammary adenocarcinoma cells coexpressing B7\u20131 (CD80) and B7\u20132 (CD86) discloses the dominant effect of B7\u20131 in the induction of anti-tumor immunity.","volume":"164","author":"Martin-Fontecha","year":"2000","journal-title":"J Immunol."},{"key":"2020021217062736400_B28","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.V82.7.2169.2169","article-title":"Serum IL-10 in Non-Hodgkin's lymphoma: a prognostic factor.","volume":"82","author":"Blay","year":"1993","journal-title":"Blood."},{"key":"2020021217062736400_B29","first-page":"119","article-title":"Loss of transforming growth factor beta 1 regulatory activity in human non Hodgkin lymphomas.","volume":"14","author":"Kopper","year":"1994","journal-title":"Anticancer Res."},{"key":"2020021217062736400_B30","doi-asserted-by":"crossref","first-page":"718","DOI":"10.4049\/jimmunol.154.2.718","article-title":"Lymphokine mRNA expression by transplantable murine B lymphocytic malignancies: tumor-derived IL-10 as a possible mechanism for modulating the anti-tumor response.","volume":"154","author":"Bost","year":"1995","journal-title":"J Immunol."},{"key":"2020021217062736400_B31","first-page":"716","article-title":"TGF\u03b2 from multiple myeloma cells inhibits activation and IL-2 responses in T lymphocytes [abstract].","volume":"92(suppl 1)","author":"Campbell","year":"1998","journal-title":"Blood."},{"key":"2020021217062736400_B32","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/10428199809059231","article-title":"The expression of T cell related costimulatory molecules in multiple myeloma.","volume":"31","author":"Brown","year":"1998","journal-title":"Leuk Lymphoma."},{"key":"2020021217062736400_B33","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1084\/jem.188.10.1849","article-title":"Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) T cells.","volume":"188","author":"Chen","year":"1998","journal-title":"J Exp Med."},{"key":"2020021217062736400_B34","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4049\/jimmunol.156.1.73","article-title":"TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10\u2013mediated pathways in tumor-bearing mice.","volume":"156","author":"Maeda","year":"1996","journal-title":"J Immunol."},{"key":"2020021217062736400_B35","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/0006-291X(89)92795-2","article-title":"Activation of the bone-derived latent TGF beta complex by isolated osteoclasts.","volume":"158","author":"Oreffo","year":"1989","journal-title":"Biochem Biophys Res Commun."},{"key":"2020021217062736400_B36","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/9525","article-title":"Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients.","volume":"6","author":"Lee","year":"1999","journal-title":"Nat Med."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/98\/10\/2992\/1678377\/h8220102992.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/98\/10\/2992\/1678377\/h8220102992.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T20:10:51Z","timestamp":1682280651000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/98\/10\/2992\/53004\/Dendritic-cells-from-patients-with-myeloma-are"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,11,15]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2001,11,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v98.10.2992","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2001,11,15]]}}}